Study Details
A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants with Opioid Use Disorder
Clinicaltrials.gov ID
Astellas Study ID
8062-CL-2221
EudraCT ID
N/A
Condition
Opioid Drug Abuse
Phase
Phase 2
Age
18 Years - 65 Years
Sex
Female & Male
Product
ASP8062
Type
Interventional
Trial Dates
Nov 2021 - Feb 2023
Masking
Triple (Participant, Investigator, Outcomes Assessor)
Enrollment number
0
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants with Opioid Use Disorder
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants with Opioid Use Disorder? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Pahl Pharmaceutical Professionals LLC
Oklahoma, United States, 73112
Hassman Research Institute
Berlin, United States, 08009
Innovative Clinical Research, Inc.
Lauderhill, United States, 33319
Segal Trials Miami Lakes Medical Research
Miami Lakes, United States, 33016
Accel Research Sites
Lakeland, United States, 33803
Collaborative Neuroscience net
Garden Grove, United States, 92845
Woodland International Research
Little Rock, United States, 72211
North Star Medical Research
Middleburg Heights, United States, 44130
Pillar Clinical Research
Richardson, United States, 75080
Artemis Institute for Clinical Research
San Diego, United States, 92103
Altea Research
Las Vegas, United States, 89102
Advanced Research for Health Improvement, LLC
Naples, United States, 34102
Revival Research Institute
Dearbon, United States, 48126